

Supplementary Table 2. The patients' information in different studies

Author	Number	Diagnosis	Population	Mean Age	Follow-up	Method	TNM (%, N)
Nalwoga H	192	1990-2002	African (Ugandan)	46.2Y (18-80)	9 M(0.5-108)	TMA and IHC	2003 (WHO) Stage 1-2: 9% (2) Stage 3: 36% (8) Stage 4: 54% (12)
Pietersen AM	295	1984-1995	Dutch	Unknown	10.2 Y	TMA and IHC	Stage 1-2: 295 samples
Choi YJ	960	1995-2002	Korean	47Y (20-80)	77.1 M(8-149)	TMA and IHC	6th AJCC Stage I : 20.2% (94) Stage II : 55.6% (534) Stage III: 24.2% (232)
Kim JH	71	2000-2002	Korean	Unknown	Unknown	IHC	TNM residual tumor classification
Arners JB	176	1996-2001	Norwegian	60Y (49-72)	69M (10-105)	TMA and IHC	Unknown
Guo BH	252	1999-2001	Chinese	47Y (26-78)	59M (4-78)	IHC	2002 (UICC) Stage I : 9.1% (23) Stage II : 37.3% (94) Stage III: 35.7% (90) Stage IV: 17.9% (45)